Overview
- Adjusted earnings were $0.87 per share on revenue of $16.65 billion, surpassing Wall Street estimates.
- Full-year adjusted EPS guidance rose to $3.00–$3.15, while revenue guidance stayed at $61–$64 billion.
- Results included a one-time $1.35 billion charge tied to a 3SBio licensing deal that reduced earnings by roughly $0.20 per share.
- The outlook reflects current tariffs on China, Canada and Mexico but excludes threatened pharmaceutical-specific levies.
- Pfizer secured a three-year tariff grace period in return for expanded U.S. investment and plans a $70 billion reshoring build-out, as it also filed a second lawsuit accusing Novo Nordisk of anticompetitive conduct in the Metsera bidding.